### Cell/Gene Tx channel feed ### [SonoThera raises $125M for non-viral gene therapy approach](https://endpoints.news/sonothera-raises-125m-for-non-viral-gene-therapy-approach/ "SonoThera raises $125M for non-viral gene therapy approach") 5 days ago ### [A father built a gene therapy for his daughter. He says an FDA request is the bottleneck](https://endpoints.news/grace-science-says-fda-jeopardizes-rare-disease-therapy/ "A father built a gene therapy for his daughter. He says an FDA request is the bottleneck") 6 days ago ### [Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases](https://endpoints.news/lilly-strikes-deal-with-ascidian-worth-up-to-1-9b-for-rna-editing-in-kidney-diseases/ "Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases") Last week ### [FDA details flexibilities for new cell and gene therapies to leverage past data](https://endpoints.news/fda-details-flexibilities-for-new-cell-and-gene-therapies-to-leverage-past-data/ "FDA details flexibilities for new cell and gene therapies to leverage past data") Last week ### [Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti](https://endpoints.news/legend-biotech-shares-first-in-vivo-car-t-data-its-next-act-after-carvykti/ "Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti") Last week ### [Epigenetic editing shows promise against chronic hep B infections](https://endpoints.news/epigenetic-editing-shows-promise-against-chronic-hep-b-infections/ "Epigenetic editing shows promise against chronic hep B infections") 2 weeks ago ### [After leaving Legend, founding scientist Frank Fan is ready to showcase his next project](https://endpoints.news/asco26-after-leaving-legend-frank-fan-is-ready-to-showcase-his-next-project/ "After leaving Legend, founding scientist Frank Fan is ready to showcase his next project") 3 weeks ago ### [Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy](https://endpoints.news/charles-river-ceo-says-it-likely-wont-be-the-last-manufacturer-to-break-away-from-cell-and-gene-therapy/ "Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy") 3 weeks ago ### [Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward](https://endpoints.news/china-gene-editing-startup-yoltech-raises-70m-to-move-crispr-therapies-forward/ "Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward") 3 weeks ago ### [Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China](https://endpoints.news/waypoint-bio-raises-20m-to-run-three-car-t-trials-in-china/ "Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China") 3 weeks ago ### [Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout](https://endpoints.news/lilly-reports-new-data-on-pcsk9-base-editing-gene-therapy-from-verve-buyout/ "Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout") 3 weeks ago ### [Fetal gene therapy inches closer. Will embryo editing follow?](https://endpoints.news/fetal-gene-therapys-progress-calls-into-question-the-taboo-on-embryo-editing/ "Fetal gene therapy inches closer. Will embryo editing follow?") 4 weeks ago ### [A Zillow-like marketplace for abandoned gene therapies goes live](https://endpoints.news/asgct26-a-zillow-like-marketplace-for-abandoned-gene-therapies-goes-live/ "A Zillow-like marketplace for abandoned gene therapies goes live") Last month ### [Encoded's gene therapy reduced seizures in Dravet syndrome](https://endpoints.news/encodeds-gene-therapy-reduced-seizures-in-dravet-syndrome/ "Encoded's gene therapy reduced seizures in Dravet syndrome") Last month ### [ASGCT dispatch: In vivo CAR-T is everywhere](https://endpoints.news/asgct-dispatch-in-vivo-car-t-is-everywhere-but-still-preclinical/ "ASGCT dispatch: In vivo CAR-T is everywhere") Last month ### [Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA?](https://endpoints.news/regenxbio-hits-duchenne-gene-therapy-milestone-eyes-2027-fda-approval/ "Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA?") Last month ### [After an apparent cure, a gene editing company struggles to repeat the magic](https://endpoints.news/after-an-apparent-cure-a-gene-editing-company-struggles-to-repeat-the-magic/ "After an apparent cure, a gene editing company struggles to repeat the magic") Last month ### [Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix](https://endpoints.news/tessera-reveals-strongest-data-yet-for-in-vivo-sickle-cell-therapy/ "Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix") Last month ### [Flagship startup says it has solved non-viral gene therapy in monkeys, but details remain murky](https://endpoints.news/flagship-startup-serif-says-it-has-solved-non-viral-gene-therapy-in-monkeys/ "Flagship startup says it has solved non-viral gene therapy in monkeys, but details remain murky") Last month ### [European regulators greenlight first clinical test of GLP-1 gene therapy](https://endpoints.news/european-regulators-greenlight-fractyl-healths-clinical-test-of-glp-1-gene-therapy/ "European regulators greenlight first clinical test of GLP-1 gene therapy") Last month ### [Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure](https://endpoints.news/atara-pierre-fabres-cell-therapy-to-get-another-shot-at-fda-approval/ "Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure") Last month ### [Exclusive: Startup aims to lift mRNA out of purgatory with more durable therapies](https://endpoints.news/former-orbital-scientists-launch-new-mrna-therapy-startup/ "Exclusive: Startup aims to lift mRNA out of purgatory with more durable therapies") Last month ### [J&J axes pair of CAR-T therapies for lymphoma, citing evolving market](https://endpoints.news/jj-axes-pair-of-car-t-therapies-for-lymphoma-citing-evolving-market/ "J&J axes pair of CAR-T therapies for lymphoma, citing evolving market") Last month ### [Lilly strikes second partnership this year for recombinase-based gene editing](https://endpoints.news/lilly-strikes-second-partnership-this-year-for-recombinase-based-gene-editing/ "Lilly strikes second partnership this year for recombinase-based gene editing") Last month